Chinese Regulator Approves DAXXIFY for Registration
The National Medical Products Administration has approved for registration, DAXXIFY, a botulinum toxin type A for injection, used to temporary improve the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult patients, a Monday filing with the Hong Kong Exchange said.
Sisram Medical's (HKG:1696) subsidiary was given the sub-license of the product by Shanghai Fosun Pharmaceutical Industrial Development for the rights to use, import, sell, and commercialize in the region.
The original licensor, the US-based Revance Therapeutics, is the right holder of the product in the region.
The company's shares were down 7% on Monday's close.
Price (HKD): $3.19, Change: $-0.24, Percent Change: -7.00%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.